Takahiro Oshina

Dr. Takahiro Oshina


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
TOTakahiro Oshina
Takahiro Oshina
TKTaketo Kawai
Taketo Kawai
YSYusuke Sato
Yusuke Sato
JMJimpei Miyakawa
Jimpei Miyakawa
YMYu Miyama
Yu Miyama
HKHaruki Kume
Haruki Kume

20 August 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
TOTakahiro Oshina
Takahiro Oshina
YYYuta Yamada
Yuta Yamada
TFTetsuya Fujimura
Tetsuya Fujimura
STSatoru Taguchi
Satoru Taguchi
YAYoshiyuki Akiyama
Yoshiyuki Akiyama
HKHaruki Kume
Haruki Kume
Background: Salvage robot-assisted radical prostatectomy (sRARP) after PSA failure in patients who underwent initial radiotherapy or focal therapy has rarely been reported in Japan. We aimed to report the oncologic and functional outcomes of the first 10 cases of sRARP. Methods: Ten patients underwent sRARP after failing to respond to initial radiotherapy or focal therapy. Initial definitive treatment included volumetric modulated arc therapy, intensity-modulated radio therapy, stereotactic body radiotherapy, heavy-ion radiotherapy, low-dose-rate brachytherapy, and high-intensity focused ultrasound. We retrospectively investigated 10 cases on oncologic and functional outcomes of sRARP. Results: The median PSA level at sRARP, amount of blood loss, and console time were 2.17 ng/mL, 100 mL, and 136 min, respectively. Positive surgical margins were found in half of the cases. Median follow-up was 1.1 years. There were no 30-day major complications. No patients had erections after sRARP. Urinary continence and biochemical recurrence (BCR) rate were 40% and 30% at 1 year after sRARP, respectively. Conclusions: Salvage RARP may be a feasible option after PSA failure in patients who underwent radiotherapy or focal therapy as initial treatment, showing acceptable BCR rate.